Trial Profile
A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2019
Price :
$35
*
At a glance
- Drugs THR 149 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Oxurion
- 18 Oct 2019 According to an Oxurion media release, data from this study were presented at major Retinal Conferences in Europe and the US including 19th Congress of European Society of Retina Specialists (EURETINA), Retina Society Annual Meeting and the American Academy of Ophthalmology Annual Meeting (AAO).
- 09 Oct 2019 Results presented in an Oxurion media release.
- 09 Oct 2019 According to an Oxurion media release, clinical update will be presented at upcoming Ophthalmology Innovation Summit (OIS) meeting which will be held on 10th October 2019, at the Hilton San Francisco Union Square.